Wockhardt Receives USFDA Nod For Treating Ophthalmic Allergies

Wockhardt has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for 0.1% ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1% ophthalmic solution is a generic version of Patanol, marketed in the US by Alcon, a subsidiary of Novartis.

The product will be manufactured in Montreal, Canada. Meanwhile, the stock closed in a positive territory on Monday’s trade at Rs 605.05 per share gaining 0.18% on the BSE. Wockhardt last USFDA approval was in March to market a generic version of Wyeth’s Zosyn, used for treating bacterial infections, in the American market.

Wockhardt Limited is a pharmaceutical and biotechnology company. The company’s businesses include manufacturing and marketing of pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.